Previous 10 | Next 10 |
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to prese...
Many Wall Street analysts reiterated their bullish views on Gene therapy company Rocket Pharmaceuticals ( NASDAQ: RCKT ) on Thursday, even after its shares fell ~17% in reaction to an update on its candidate for Danon Disease RP-A501. After an end-of-Phase 1 meeting, the compa...
Gene therapy company Rocket Pharmaceuticals ( NASDAQ: RCKT ) announced Thursday that, subject to FDA feedback, the company will start the initial component of a pivotal global trial for its Danone disease candidate RP-A501 in H1 2023. A genetically inherited disorder, Danon Disease re...
Based on ongoing FDA discussion, Rocket to pursue a biomarker-based composite endpoint for a single arm, open-label pivotal trial with a natural history comparator Initiation of initial component of global study anticipated in 1H’23 Rocket Pharmaceuticals, Inc. ...
Sustained genetic and phenotypic correction and concomitant hematologic stabilization observed in at least six of 10 evaluable FA patients between 12 and 36 months after RP-L102; a seventh patient potentially demonstrates engraftment and stabilization after 36 months Robust and sustained ...
Acquisition further extends Rocket’s leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and s...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will part...
NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seacoast Banking Corporation of ...
NEW YORK, NY / ACCESSWIRE / November 4, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Professional Holding Corp. (NASDA...
Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q3 GAAP EPS of -$0.87 misses by $0.08 . Cash position. Cash, cash equivalents and investments as of September 30, 2022, were $306.5 million. Shares outstanding. 67,838,803 shares of common stock were issued and...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...